Literature DB >> 33730335

Diabetic Ketoacidosis at Emergency Department Presentation During the First Months of the SARS-CoV-2 Pandemic in Israel: A Multicenter Cross-Sectional Study.

Ron Jacob1, Giora Weiser2, Danna Krupik3, Dania Takagi4, Shuny Peled5, Naama Pines6, Saar Hashavya6, Hagar Gur-Soferman7, Shirly Gamsu8, Or Kaplan9, Michal Maimon9, Shahar Oren10, Gabi Padeh11, Itai Shavit12.   

Abstract

INTRODUCTION: We aimed to examine the impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic on diabetic ketoacidosis (DKA) rates in children with type 1 diabetes (T1D).
METHODS: A retrospective cross-sectional study of 11 Israeli pediatric emergency departments (ED) was conducted. Children with T1D who attended the ED between March 1, 2020 and May 31, 2020 were compared with those who attended the ED between March 1, 2019 and May 31, 2019.
RESULTS: Overall, 150 and 154 children with T1D attended the EDs during the 3-month study periods in 2020 and 2019, respectively. Among patients with established T1D, DKA rates significantly increased in 2020 compared to 2019 [38/64 (59.3%) vs 31/74 (41.9%); p < 0.043]. There was a non-statistically significant trend toward a higher rate of DKA in patients with newly diagnosed T1D [46/86 (53.4%) vs 31/80 (38.7%); p = 0.063]. No differences were observed in the rates of severe DKA in 2020 compared to 2019 among patients with established T1D [10/64 (15.6%) vs 6/74 (8.1%); p = 0.184], and newly diagnosed T1D [16/86 (18.6%) vs 14/80 (17.5%); p = 0.858]. No differences were observed in the rates of intensive care unit admissions in 2020 compared to 2019 among patients with established T1D [14/64 (21.8%) vs 14/74 (18.9%); p = 0.672], and newly diagnosed T1D [26/86 (30.2%) vs 21/80 (26.2%); p = 0.977].
CONCLUSIONS: Increased rates of DKA in children with established T1D were observed during the first 3 months of the outbreak in Israel. The findings suggest that the severity of DKA at ED presentation in children with T1D was not influenced by the pandemic.

Entities:  

Keywords:  Coronavirus; Diabetes; Ketoacidosis; Pandemic

Year:  2021        PMID: 33730335      PMCID: PMC7965330          DOI: 10.1007/s13300-021-01049-3

Source DB:  PubMed          Journal:  Diabetes Ther        ISSN: 1869-6961            Impact factor:   2.945


Key Summary Points

Digital Features

This article is published with digital features, including a summary slide to facilitate understanding of the article. To view digital features for this article go to 10.6084/m9.figshare.14153168.

Introduction

Diabetic ketoacidosis (DKA) is a severe acute complication of diabetes arising from a relative insulin deficiency, which occurs more often in children with type 1 diabetes (T1D) and in the setting of moderate to severe illness [1]. Recent studies found an increase in the rates of severe DKA in patients with newly diagnosed T1D during the severe acute respiratory coronavirus 2 (SARS-CoV-2) pandemic [2-4]. There have been no studies that examined the impact of the SARS-CoV-2 pandemic on DKA rates in emergency department (ED) patients with established T1D. We examined DKA at ED presentation in patients with established T1D and newly diagnosed T1D (diagnosis at admission) during the first 3 months of the SARS-CoV-2 outbreak in Israel.

Methods

Study Design

A retrospective cross-sectional study of 11 pediatric EDs was conducted. Children with T1D who attended the ED between March 1, 2020 and May 31, 2020 were compared with those who attended the ED between March 1, 2019 and May 31, 2019.

Participant Selection and Data Source

Only children who were coded as having a diabetes-related presentation as their reason for the visit were included. The following variables were abstracted: age, sex, type of T1D (newly diagnosed, established), presence of DKA, period of admission (pandemic, pre-pandemic), serum pH and bicarbonate levels on admission, and intensive care unit admission. Chart review was conducted in accordance with published methods for retrospective chart review studies in emergency medicine [5]. The study was approved by the institutional review boards of the participating hospitals, and was performed in accordance with the principles embodied in the Declaration of Helsinki. Informed consent was not required because of the retrospective nature of the study. DKA was defined as a pH level < 7.3. Severe DKA was defined as a pH level < 7.1 [6].

Statistical Analysis

Fisher’s exact test was used to compare proportions between groups. The non-parametric Mann–Whitney U test was used to compare continuous variables. A two-sided p < 0.05 was considered statistically significant. All statistics were calculated using StatsDirect statistical software (V.2.6.6, StatsDirect Limited, Cheshire, UK).

Results

Overall, 48,176 and 77,477 patients visited the pediatric EDs during the study periods in 2020 and 2019, respectively. One-hundred and fifty patients with T1D and a median age (interquartile range, IQR) of 12.0 (8.7–14.1) years, and 154 patients with T1D and a median (IQR) age of 12.0 (8.7–15.0) years attended the pediatric EDs during the 2020 and 2019 study periods, respectively. There were 64 and 74 patients with established T1D in 2020 and 2019, respectively; and 86 and 80 patients with newly diagnosed T1D in 2020, and 2019, respectively (Table 1).
Table 1

Comparison of patients with newly diagnosed and established type 1 diabetes during the pandemic (March 1–May 31, 2020) and pre-pandemic (March 1–May 31, 2019) periods

Pandemic period (n = 86)Pre-pandemic period (n = 80)p value
Newly diagnosed type 1 diabetes
Patients with DKAa, n (%)46 (53.4)31 (38.7)0.063
Patients with severe DKAb, n (%)16 (18.6)14 (17.5)0.858
Serum pH level, mean (SD)7.24 (0.16)7.26 (0.17)0.142
Serum bicarbonate level, mmol/L, mean (SD)16.3 (7.8)18.1 (8.6)0.091

SD standard deviation, DKA diabetic ketoacidosis

aDiabetic ketoacidosis: pH level < 7.3

bSevere diabetic ketoacidosis: pH level < 7.1

Comparison of patients with newly diagnosed and established type 1 diabetes during the pandemic (March 1–May 31, 2020) and pre-pandemic (March 1–May 31, 2019) periods SD standard deviation, DKA diabetic ketoacidosis aDiabetic ketoacidosis: pH level < 7.3 bSevere diabetic ketoacidosis: pH level < 7.1 Distributions of DKA severity categories (mild, moderate, severe) are shown in Fig. 1.
Fig. 1

Rates of diabetic ketoacidosis (DKA) in patients with newly diagnosed and established type 1 diabetes on emergency department admission during the pandemic (March 1–May 31, 2020) and pre-pandemic (March 1–May 31, 2019) periods. Definitions of DKA severity [6]: DKA, pH level < 7.3; mild DKA, 7.2 < pH level < 7.3; moderate DKA, 7.1 < pH level < 7.2; severe DKA, pH level < 7.1

Rates of diabetic ketoacidosis (DKA) in patients with newly diagnosed and established type 1 diabetes on emergency department admission during the pandemic (March 1–May 31, 2020) and pre-pandemic (March 1–May 31, 2019) periods. Definitions of DKA severity [6]: DKA, pH level < 7.3; mild DKA, 7.2 < pH level < 7.3; moderate DKA, 7.1 < pH level < 7.2; severe DKA, pH level < 7.1 Among patients with established T1D, the rate of DKA significantly increased in the pandemic period compared to the pre-pandemic period [38/64 (59.3%) vs 31/74 (41.9%), p < 0.043], Table 1. There was a non-statistically significant trend toward a higher rate of DKA in patients with newly diagnosed T1D [46/86 (53.4%) vs 31/80 (38.7%), p = 0.063], Table 1. No differences were observed in the rates of severe DKA in 2020 compared to 2019 among patients with established T1D [10/64 (15.6%) vs 6/74 (8.1%); p = 0.184], and newly diagnosed T1D [16/86 (18.6%) vs 14/80 (17.5%); p = 0.858]. No differences were observed in the rates of intensive care unit admissions in 2020 compared to 2019 among patients with established T1D [14/64 (21.8%) vs 14/74 (18.9%); p = 0.672], and newly diagnosed T1D [26/86 (30.2%) vs 21/80 (26.2%); p = 0.977]. None of the patients died. Thirteen/86 (15.1%) patients with newly diagnosed T1D visited the ED during the lockdown period (March 17, 2020 to April 17, 2020), 9/13 (69.2%) had DKA at presentation. Thirteen/64 (20.3%) patients with established T1D visited the ED during the lockdown period, 9/13 (69.2%) had DKA at presentation.

Discussion

This study reveals a 37.8% reduction in pediatric ED visits during the first 3 months of the pandemic in Israel. Parents and caregivers’ perception of the ED as a place of infection is maybe the cause of the decrease in ED utilization [7]. The main finding of the current study is the increased rate of DKA in children with established T1D who attended the ED because of a diabetes-related problem during the first 3 months of the pandemic period. The lower serum pH and bicarbonate levels at ED presentation during the pandemic period compared with the pre-pandemic period support this finding (Table 1). Another important finding is that there were no differences in the rate of severe DKA at ED presentation (Table 1) and in the rate of intensive care unit admissions due to DKA between the two study periods. These findings suggest that the severity of DKA at ED presentation of patients with T1D was not influenced by the pandemic. Although not statistically significant, there seems to be a trend toward a higher rate of DKA during the pandemic period in patients with newly diagnosed T1D as well (53.4% vs 38.7%, Table 1). This finding was also reported in recent studies from Germany, Italy, and Australia [2-4]. There were no differences in serum pH and bicarbonate levels, rates of severe DKA, and rates of ICU admissions between the two study periods. These findings suggest that children with newly diagnosed T1D were perhaps less influenced by the pandemic. We found that during lockdown, nearly 70% of patients with the newly diagnosed T1D and nearly 70% of the patients with established T1D presented with DKA; however, the small sample size limits interpretation of these findings and suggests the need for further study. The current study has some limitations. First, we investigated only the first 3 months of the SARS-CoV-2 pandemic. Our results, therefore, may not apply to the later periods of the pandemic. Second, because of the retrospective cross-sectional design of the study, conclusions of a causal nature cannot be drawn from the results. Third, since DKA prevalence at T1D diagnosis varied across countries, the findings of this study may not be generalizable to other populations [1].

Conclusions

Study findings provide evidence for the increased rates of DKA in children with established T1D during the first months of the pandemic in Israel. The findings suggest that the severity of DKA at ED presentation in children with T1D was not influenced by the pandemic. Since the pandemic is still progressing, it is important to enhance patient and clinician awareness of this phenomenon while simultaneously exploring possible causes such as delayed ED presentation or suboptimal follow-up care during the pandemic.
Why carry out this study?
Diabetic ketoacidosis (DKA) is a severe acute complication of diabetes which occurs more often in children with type 1 diabetes (T1D).
We examined DKA at emergency department presentation in patients with established and newly diagnosed T1D during the SARS-CoV-2 outbreak in Israel.
What was learned from the study?
We found that the rates of DKA significantly increased during the pandemic period among patients with established T1D.
There was a trend toward higher rates of DKA among patients with newly diagnosed T1D.
Since the pandemic is still progressing, it is important to enhance awareness of this phenomenon while simultaneously exploring possible causes.
  1 in total

1.  Increased paediatric presentations of severe diabetic ketoacidosis in an Australian tertiary centre during the COVID-19 pandemic.

Authors:  C Lawrence; R Seckold; C Smart; B R King; P Howley; R Feltrin; T A Smith; R Roy; P Lopez
Journal:  Diabet Med       Date:  2020-10-23       Impact factor: 4.359

  1 in total
  6 in total

1.  Has the COVID-19 Pandemic Affected the Prevalence of Diabetic Ketoacidosis in Polish Children with Newly Diagnosed Type 1 Diabetes? An Example of the Largest Polish Pediatric Diabetes Center (Upper Silesia-Katowice, Poland).

Authors:  Ewa Rusak; Sebastian Seget; Maksymilian Macherski; Natalia Furgał; Przemysław Dyś; Przemysława Jarosz-Chobot
Journal:  Healthcare (Basel)       Date:  2022-02-11

2.  Incidence of Diabetic Ketoacidosis Among Pediatrics With Type 1 Diabetes Prior to and During COVID-19 Pandemic: A Meta-Analysis of Observational Studies.

Authors:  Osamah M Alfayez; Kholood S Aldmasi; Nada H Alruwais; Nouf M Bin Awad; Majed S Al Yami; Omar A Almohammed; Abdulaali R Almutairi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-09       Impact factor: 5.555

3.  Trends in Type 1 Diabetic Ketoacidosis During COVID-19 Surges at 7 US Centers: Highest Burden on non-Hispanic Black Patients.

Authors:  Andrew R Lavik; Osagie Ebekozien; Nudrat Noor; G Todd Alonso; Sarit Polsky; Scott M Blackman; Justin Chen; Sarah D Corathers; Carla Demeterco-Berggren; Mary Pat Gallagher; Margaret Greenfield; Ashley Garrity; Saketh Rompicherla; Robert Rapaport; Nana-Hawa Yayah Jones
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

4.  Incidence of diabetic ketoacidosis during COVID-19 pandemic: a meta-analysis of 124,597 children with diabetes.

Authors:  Anas Elgenidy; Ahmed K Awad; Khaled Saad; Mostafa Atef; Hatem Helmy El-Leithy; Ahmed A Obiedallah; Emad M Hammad; Faisal-Alkhateeb Ahmad; Ahmad M Ali; Hamad Ghaleb Dailah; Amira Elhoufey; Samaher Fathy Taha
Journal:  Pediatr Res       Date:  2022-08-11       Impact factor: 3.953

5.  Presentations of children to emergency departments across Europe and the COVID-19 pandemic: A multinational observational study.

Authors:  Ruud G Nijman; Kate Honeyford; Ruth Farrugia; Katy Rose; Zsolt Bognar; Danilo Buonsenso; Liviana Da Dalt; Tisham De; Ian K Maconochie; Niccolo Parri; Damian Roland; Tobias Alfven; Camille Aupiais; Michael Barrett; Romain Basmaci; Dorine Borensztajn; Susana Castanhinha; Corinne Vasilico; Sheena Durnin; Paddy Fitzpatrick; Laszlo Fodor; Borja Gomez; Susanne Greber-Platzer; Romain Guedj; Stuart Hartshorn; Florian Hey; Lina Jankauskaite; Daniela Kohlfuerst; Mojca Kolnik; Mark D Lyttle; Patrícia Mação; Maria Inês Mascarenhas; Shrouk Messahel; Esra Akyüz Özkan; Zanda Pučuka; Sofia Reis; Alexis Rybak; Malin Ryd Rinder; Ozlem Teksam; Caner Turan; Valtýr Stefánsson Thors; Roberto Velasco; Silvia Bressan; Henriette A Moll; Rianne Oostenbrink; Luigi Titomanlio
Journal:  PLoS Med       Date:  2022-08-26       Impact factor: 11.613

Review 6.  The global impact of COVID-19 pandemic on the incidence of pediatric new-onset type 1 diabetes and ketoacidosis: A systematic review and meta-analysis.

Authors:  Masoud Rahmati; Maryam Keshvari; Shahrzad Mirnasuri; Dong K Yon; Seung W Lee; Jae Il Shin; Lee Smith
Journal:  J Med Virol       Date:  2022-07-22       Impact factor: 20.693

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.